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Novel engineered nanoparticles (NPs), nanomaterial (NM) products and composites, are continually
emerging worldwide. Many potential benefits are expected from their commercial applications; however,
these benefits should always be balanced against risks. Potential toxic effects of NM exposure have been
highlighted, but, as there is a lack of understanding about potential interactions of nanomaterials (NMs) with
biological systems, these side effects are often ignored. NPs are able to translocate to the bloodstream, cross
body membrane barriers effectively, and affect organs and tissues at cellular and molecular levels. NPs may
pass the blood-brain barrier (BBB) and gain access to the brain. The interactions of NPs with biological milieu
and resulted toxic effects are significantly associated with their small size distribution, large surface area to
mass ratio (SA/MR), and surface characteristics. NMs are able to cross tissue and cell membranes, enter into
cellular compartments, and cause cellular injury as well as toxicity. The extremely large SA/MR of NPs is also
available to undergo reactions. An increased surface area of the identical chemical will increase surface
reactivity, adsorption properties, and potential toxicity. This review explores biological pathways of NPs, their
toxic potential, and underlying mechanisms responsible for such toxic effects. The necessity of toxicological
risk assessment to human health should be emphasised as an integral part of NM design and manufacture.
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Abstract: Novel engineered nanoparticles (NPs), nanomaterial (NM) products and composites, are
continually emerging worldwide. Many potential benefits are expected from their commercial
applications; however, these benefits should always be balanced against risks. Potential toxic effects
of NM exposure have been highlighted, but, as there is a lack of understanding about potential
interactions of nanomaterials (NMs) with biological systems, these side effects are often ignored.
NPs are able to translocate to the bloodstream, cross body membrane barriers effectively, and affect
organs and tissues at cellular and molecular levels. NPs may pass the blood–brain barrier (BBB) and
gain access to the brain. The interactions of NPs with biological milieu and resulted toxic effects are
significantly associated with their small size distribution, large surface area to mass ratio (SA/MR),
and surface characteristics. NMs are able to cross tissue and cell membranes, enter into cellular
compartments, and cause cellular injury as well as toxicity. The extremely large SA/MR of NPs is
also available to undergo reactions. An increased surface area of the identical chemical will increase
surface reactivity, adsorption properties, and potential toxicity. This review explores biological
pathways of NPs, their toxic potential, and underlying mechanisms responsible for such toxic effects.
The necessity of toxicological risk assessment to human health should be emphasised as an integral
part of NM design and manufacture.
Keywords: inhalation; nanoparticles; nanomaterials; physicochemical properties; toxicity mechanism;
risk assessment
1. Introduction
Nanotechnology can be described as the science of precise manipulation and design of matter at
the nanoscale level of approximately 1–100 nanometers (nm). Detailed terminology and definitions
related to different types of nano-objects such as nanoparticle, nanofibre, and nanoplate have
been described [1,2]. Nanotechnology has grown to a multibillion dollar industry worldwide [3].
Engineered nanomaterials (NMs) with their unique physicochemical characteristics are rapidly
being implemented in the various fields of medicine, pharmaceutics, biotechnology, energy
production, environmental sciences, crop protection, transportation, housing, and electronics [4–6].
Novel engineered NMs and composites are continually emerging with the potential for significant
commercial applications.
Engineered NMs can be manufactured from chemical elements such as metals, metal oxides,
sulphides or selenides, carbon, polymers, and biological molecules such as lipids, carbohydrates,
peptides, proteins, and nucleic acid oligomers [3]. The geometry of manufactured NMs may range
from isometric NPs to one-dimensional (1D; nanofibres or nanotubes), and two-dimensional (2D;
plate-like or disk-like NMs) forms (Table 1). Therefore, to represent the diversity of engineered NMs,
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a matrix based on the combination of geometry and chemistry can be used for the classification of
engineered NMs [3].
Table 1. Nano-objects; related terms and geometrical characteristics.
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The most commonly implemented NMs have been made of transitional metals (e.g., silver, gold), 
carbon (e.g., fullerenes, single and multi-walled carbon nanotubes, graphene), and metal oxides  
(e.g., ZnO, TiO2). Examples of high volume, commercial NMs include nanosilver, fullerenes, 
quantum dots, carbon nanotubes, and metal oxide NPs [3]. NPs have already been applied in 
sunscreens and cosmetic products, food additives, self-cleaning surfaces, disinfectants and clothing, 
batteries, fuel additives, and other products. A variety of NMs have been engineered to enhance 
medical devices, their functionality and reliability. Nanostructured materials may be applied to 
surfaces such as biomedical implants to enhance their biocompatibility, incorporated into 
nanostructured solids or composites to improve strength, conductivity, and durability, and 
fabricated into complex, active structures for chemical or biological sensors or other devices [3]. NMs 
have been promoted in cell and tissue engineering, development of medical devices, encapsulation 
and drug delivery, diagnostics, and genes [7]. An overview of applications of polymeric nano-carriers 
is provided for respiratory drug and gene delivery [8]. 
The development of NPs for biomedical applications and drug delivery is rapidly expanding. 
Future nanomedicine is projected to have an enormous impact on both diagnosis and treatment, 
primarily in the field of cancer nanotechnology [9]. The application of nanotechnology to medicine is 
significant due to the ability of NPs to resemble the dimensions of essential components of biological 
molecules, to be able to cross body membrane barriers more effectively, and to affect organs and 
tissues at the cellular and molecular levels. Biological responses to NMs at the protein and cellular 
levels differ from those observed for conventional materials. NPs and NM products may introduce 
enhanced biological effects at cellular and molecular target levels, but the potential pitfalls or 
undesired effects of NMs in biological systems are also an important issue that should not be  
ignored [10–13]. Although NPs such as some polymeric NPs may exhibit biocompatible behaviour  
in biological systems, prior to their therapeutic application, NPs should undergo a comprehensive 
physicochemical characterization in both dry and wet conditions. Examples of biosafety and 
biocompatibility investigations of specific NMs used in regenerative medicine have been  
reviewed [13]. These include quantum dots, silica, and polymer NPs that are mostly used for 
fluorescence imaging; super-paramagnetic iron oxide NPs used for magnetic resonance imaging; and 
gold NPs that are used for photoacoustic imaging [13]. 
Available research has indicated that ultrafine particles (UFPs) often induce mild yet significant 
pulmonary inflammatory responses as well as systemic effects [14]. Pulmonary exposure to NPs 
induces a greater inflammatory response compared to larger particles of conventional material at 
identical mass concentrations [15]. Following the exposure of human fibroblasts to ZnO and TiO2 
NPs, cell viability was significantly reduced in a dose-dependent manner using the MTS Tetrazolium 
Salt assay [16]. In vitro exposure of A549 cells to micro- and nanosized copper(II) oxide induced cell 
viability reduction in a dose-dependent manner; however, NPs reduced the cellular metabolic 
activity more severely [17]. 
Serious damage to the human lung was reported in seven female workers who were exposed to 
polyacrylate containing NPs over a 5–13 month exposure period. All seven workers presented with 
shortness of breath and pleural effusions [18]. The compound that was stated to be polyacrylic ester 
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The most commonly implemented NMs have been made of transitional metals (e.g., silver ld),
carbon (e.g., fullerenes, single and multi-walled carbon nanotubes, graphene), and metal oxides (e.g.,
ZnO, TiO2). Examples f high volume, co mercial NMs include nanosilv r, full renes, quantum
dots, carbon nanotube , and metal oxide NPs [3]. NPs h ve alre dy been applied i sunscreens
and cosm tic products, food ditiv s, self-cleaning surfaces, disinf ctants a d clothing, batteries,
fuel addit ves, and other products. A variety of NMs have been ngine red to enhance medical
devices, their functionality an reliability. Nanostructured materials ay be applied to surfaces such
as biomedical implants to enhance their bioco patibility, incorporated into nanostructured solids
or composites to improve strength, conductivity, and durability, and fabricated into complex, active
structures for chemical or biological sensors or other devices [3]. NMs have been promoted in cell and
tissue engineering, development of medical devices, encapsulation and drug delivery, diagnostics, and
genes [7]. An overview of applications of polymeric nano-carriers is provided for respiratory drug and
gen elivery [8].
The developme t of NPs for bi medical applications and drug deliver is rapidly expanding.
Future anome icine is projected to have an normous impact on both diagn sis and treatment,
primarily in the field of cance nan technology [9]. Th application of nanotechn logy o medici e is
significant due o th ability of NPs to res mble the d mensions of essential com onents of biological
molecules, to be able to cr ss body membrane barriers ore effectively, and to affect organs and tissues
at the cellul r and molecular levels. Biological res onses to NMs t the protein and cellular levels
differ from those observed for conventional materials. NPs and NM products may introduce enhanced
biological effects at cellular and molecular target levels, but the potential pitfalls or undesired effects of
NMs in biological systems are also an important issue that should not be ignored [10–13]. Although NPs
such as some polymeric NPs may exhibit biocompatible behaviour in biological systems, prior to their
therapeutic application, NPs should undergo a comprehensive physicochemical characterization in
both dry and wet conditions. Ex mples of biosafety and biocompatibility investigations of specific
NMs used in regenerative medicine have been reviewed [13]. These include quantum dots, silica, and
polymer NPs th t are mostly u e for fluorescence imaging; super-paramagnetic iron oxide NPs used
for magnetic resonance imaging; and gold NPs that are used or photoacoustic imaging [13].
Available res rch has indicated that ultrafine particles (UFPs) oft n induce mild yet significant
pulmonary inflammatory responses as well as systemic effects [14]. Pulmonary exposure to NPs
induces a greater inflammatory response compared to larger particles of conventional material at
identical mass concentrations [15]. Following the ex sure of human fibroblasts to ZnO and TiO2
NPs, cell viability was significantly reduced in a dose-dependent manner using the MTS Tetrazolium
Salt assay [16]. In vitro exposure of A549 cells to micro- and nanosized copper(II) oxide induced cell
viability reduction in a dose-dependent manner; however, NPs reduced the cellular metabolic activity
more severely [17].
Serious damage to the human lung was reported in seven female workers who were exposed to
polyacrylate containing NPs over a 5–13 month exposu e pe iod. All seven workers presented with
shortness of breath and pleural effusions [18]. The compound that was stated to be polyacrylic ester
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consisted of NPs of 30 nm, confirmed by electron microscopy analysis of both the paste compound
used and workplace dust. Several cases of human exposure to NPs that caused symptoms such as
bronchiolitis, respiratory distress syndrome, and death have been reviewed [19]. While the potential
toxic effects of NM exposure have been highlighted as a concern, the possible interactions of NMs with
biological systems and the precise mechanisms of their toxic actions have yet to be understood.
As research and business both continue to focus on nanotech products, more research is also
needed to assess the potential adverse outcomes of NPs. Toxicological risk assessment should be
considered as an integral part of NM design and manufacture to ensure the health and safety of
workers, consumers, and the environment. Nanotoxicology is a new discipline of toxicology that aims
to precisely characterise the toxicity of NPs. Toxicological risk assessment of NPs involves hazard
identification, dose-response assessment, exposure assessment, and risk characterisation. Both in vivo
and in vitro toxicity methods are required for a comprehensive toxicity assessment of NPs. In the area
of chronic toxicity testing such as anti-cancer research, in vivo methods are preferred. However, recent
innovations in science and cell culture technology has allowed the development of alternative in vitro
assay systems that are predictive, representative, and suitable for toxicity screening, e.g., for drug
delivery of NPs. In vitro test methods have the potential to be implemented as screening tools to
understand potential toxicity mechanisms of NPs [16,20,21].
The potential risks of NPs and NM products need to be assessed to understand the precise
mechanisms responsible for such toxic effects and ultimately prevent human adverse effects. In this
review, potential biological pathways of NPs and their toxic effects are identified and possible
mechanisms of such effects are investigated. Further, recent advances and limitations related to
the risk assessment and risk management of inhaled NPs are discussed.
2. Nanoparticle Exposure and Biokinetic Pathways
With the exponential increase of production and commercialisation of nanotechnology-based
products, the pattern of human exposure to particulates has changed significantly [4,5]. NPs may
enter into the human body via inhalation, dermal, oral, and injection routes either unintentionally
or deliberately (Figure 1). In either case, the ability of NPs to cross biological barriers, such as the
skin, gastrointestinal (GI) tract, or blood–brain barrier (BBB), is a prerequisite for their success [9].
Research findings on dermal absorption and skin penetration of NPs are inconsistent, and more
data is needed to determine whether skin provides a route of entry of NPs into the body or target
tissues [22]. While injection, oral, and dermal routes may serve as important routes of deliberate entry
for nanoscale therapeutic and cosmetic products, inhalation is the most significant route of entry for
occupational exposures to NPs. The toxicological perspectives of inhaled therapeutics and NPs have
been reviewed [21].
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Dashed arrows: Potential routes; CNS: Central nervous system; PNS: Peripheral nervous system;
GI: Gastrointestinal; IV: Intravenous.
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Inhalation and deposition of particulates in the human respiratory tract is a size-dependent
cascade in which the size distribution of particles plays a major role in determining particulate airborne
behaviour [20,23]. Larger particles often are impacted in the nasopharyngeal region (5–30 µm), and
smaller particles (1–5 µm) are deposited in the tracheobronchial region. However, very small particles
including submicron particles (<1 µm) and NPs (<100 nm) are able to penetrate deeply into the alveolar
region, where the removal mechanisms are not adequate [24–26].
While the human respiratory tract has evolved with both structural and functional barriers to
deal with inhaled particulates, it cannot always sufficiently deal with the wide range of inhaled
materials [27–29]. Depending how deeply particles are deposited, a longer time will be required
to eliminate them from the lung, and greater adverse health effects may also be expected
due to particle-tissue and particle-cell interactions [29]. There is evidence that overall alveolar
macrophage-mediated clearance that functions to remove inhaled particles cannot deal with NPs
adequately, potentially enabling them to come into close contact with the alveolar epithelium and enter
the blood stream [30–33]. NPs are too small to be efficiently recognised and phagocytised by alveolar
macrophages unless they form larger particles by aggregation or agglomeration [3]. While insoluble
particles may reside in the lung indefinitely [24,25,33], very small particles have the potential to cross
the lung epithelial tissue barrier and readily reach other target organs through the blood stream [14].
While access to the central nervous system (CNS) is generally restricted by the BBB, inhaled
NPs have the potential to cross this protective barrier and enter the brain through the blood.
During inhalation, olfactory uptake is also another pathway that may provide a bypass for neuronal
transport of NPs directly from the nose to the brain (Figure 1).
Potential biological pathways of NPs including routes of exposure, absorption, biodistribution,
and translocation and excretory pathways are summarised in Figure 1. Following absorption and
systemic translocation, NPs have the potential to bio-accumulate in peripheral organs or be excreted
through faeces or urine [3,19]. The liver acts as a biological filtration system by the sequestration of
30%–99% of absorbed NPs from the bloodstream, which potentially increases toxicity at the hepatic
cellular level [34]. Most NPs are known to be taken up by non-parenchymal hepatocytes. NPs that
interact with hepatocytes can be cleared from the body via the hepatobiliary excretory pathway.
Once biological pathways and clearance timeframes of NPs are understood, biological monitoring
methods can be developed to characterise and quantify NPs in biological systems. Such methods can
be developed based on imaging techniques essential to confirm their presence and to characterise
NPs in tissues associated with quantitative analytical methods [19]. In addition to biomarkers of
exposure, biomarkers of effects may also be developed based on different interactions of NPs with
target molecules, cells, and tissues. Toxicokinetic studies are able to identify appropriate biological
samples that can be used in biometrology of NPs.
Methods applied in toxicokinetic studies of inhaled NPs have been reviewed [19]. Toxicokinetic studies
suggest that NPs may preferably enter via respiratory and oral routes with possible systemic
translocation, resulting in bioaccumulation in the peripheral organs or elimination via faeces and
urine. An integrated two-step approach was developed to evaluate the biokinetics of inhaled NPs [35].
In this approach, a combined in vitro and in silico methods was implemented to assess the pulmonary
translocation and biotransformation of gold (Au) NPs. The combination of in vitro and in silico methods
was able to accurately estimate the in vivo biokinetics of inhaled/instilled AuNPs.
3. Nanotoxicity and the Potential Mechanisms
Exposure to UFPs has significantly increased respiratory and cardiovascular morbidity and
mortality rates [34,36–40]. Combustion-derived NPs (CDNPs) are an integral constituent of urban air
pollution, or PM2.5, and lead to these adverse health outcomes [38]. Diesel engines are a major source of
particles that include high levels of NPs smaller than 50 nm [41]. CDNPs that contain both metallic and
organic NPs have the potential to translocate and access the brain and other organs [42]. Ultimately, at
the target sites, diverse mechanisms can possibly be responsible for their biological effects, such as the
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generation of reactive oxygen species (ROS), oxidative stress, mitochondrial agitation, inflammation,
reticulo-endothelial uptake, protein alteration, phagocytosis impairment, endothelial malfunction,
neoantigen generation, changed cell cycle regulation, and DNA damage [13,43,44].
Particle toxicity is associated with several parameters, mainly particle type, concentration
and size distribution, frequency and duration of exposure, and pulmonary ventilation [25,45,46].
However, when properties of new-generation engineered NPs were compared to larger particles,
significant differences were observed, such as a high number and surface area per unit volume, more
reactivity, and protein and lipid absorption (corona formation) at the primary and secondary target
sites [3]. The biological impacts of NPs that are related to their unique physicochemical properties can
be summarised in Table 2 (modified from [20]).
Table 2. Nanomaterial properties and possible biological effects.
Nanomaterial Properties Potential Biological Effects
Size/size distribution
(aerodynamic, hydrodynamic)
Crossing tissue and cell membranes
Cellular injury
Phagocytosis impairment, breakdown in defense mechanisms
Migration to other organs














Protein and DNA damage
Insolubility or low water solubility Bioaccumulation inside living systems such as human cells, tissues and lungs
Potential long-term effects
Agglomeration/aggregation Interruption of cellular processes
Cellular injury
Nanoscale properties that formulate NMs behaving differently are also able to affect their
behaviour in biological systems [9,34]. While size distribution is the most significant parameter,
other factors such as particle morphology, density, surface area, solubility, and reactivity are also
essential for the evaluation of their biological interactions. Subdividing the bulk material into smaller
parts can alter toxicity and explosive properties [36,37]. By decreasing the particle size, the specific
surface area increases, providing a greater proportion of its atoms to be displayed on the surface [13].
Inert materials, such as TiO2, can become more reactive in the nanoscale range, probably due to a
reduction in the size of the particles [11,14,38]. Apart from bulk chemistry, nanosize structures of a
chemical may alter optical, mechanical, and electrical properties, as well as chemical reactivity, leading
to different cellular uptake and interaction with biological tissues and unpredicted effects [3,9].
Nanoscale properties may change with the method of production, preparation, and storage or
when introduced into the biological system [3,13]. Depending on the exposure profile and target
cells, cellular responses can be minimal/reversible and can be recovered by the activation of adaptive
responses, or they can be severe or irreversible and lead to a significant alteration of cellular structure
and function as well as total cellular death or necrosis. The cytotoxicity of several NPs including carbon
nanotubes, TiO2, quantum dots, and gold and silver NPs has been reviewed [12]. In addition to their
physicochemical properties, the production of toxic ions, fibrous structures, high surface charge, and
generation of radical species have been highlighted as potential key factors inducing cytotoxic effects.
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The nanoscale size distribution of NPs plays a significant role in their potential toxicity and
their ability to cross tissue and cell membrane barriers and enter into individual cells [47–49].
Internalized NPs may interact with different subcellular compartments [29]. For example, particles
smaller than 50 nm appear to enter cells and subcellular organelles such as mitochondria and the
nucleus by passive diffusion [50,51]. In addition, the very small size may lead to a direct cellular injury
caused by particle-cell interactions [13]. Importantly, NPs such as CDNPs and their constituents may
enter the blood or the CNS, inducing direct effects on cardiac and cerebral functions [42,52]. Metal oxide
NPs (e.g., Fe2O3, Y2O3 and ZnO) have been internalized within human vascular endothelial cells in a
dose-dependent manner proportional to the concentration in the culture medium [49].
Overall, clearance mechanisms of the human body are not able to deal sufficiently with nanosized
materials, as there is evidence that human alveolar macrophages with the physiological function to
remove inhaled particles cannot deal with NMs less than 70 nm, hence providing them with deep
access into the alveolar region and the blood stream [31,33]. The phagocytic function of the alveolar
macrophages was impaired following exposure to ultrafine carbon particles at 1 µg/mL and higher
concentrations [30]. Although high aspect ratio NMs can be recognised by macrophages, they undergo
incomplete uptake or frustrated phagocytosis [53]. Exposure of human monocytic cells to nanotubes
induced phagocytosis impairment, suggesting that the ability of macrophages to remove nanofibres
from the lung may be reduced [32]. CDNPs and their components have the potential to translocate to
other organs [42]. At their target organs, NMs may trigger mediators and promote inflammatory or
immunological responses [52]. It has been reported that SWCNTs (single-walled carbon nanotubes)
translocate from the alveoli into the interstitium of the lung, promoting collagen deposition and
interstitial fibrosis [54].
Nanoscale material structures have the potential to induce greater toxicity due to an expanded
SA/MR available to undergo reactions. For example, the surface area of airborne 5-nm NPs is
1000 times higher than the surface area of 5-µm particles of the same chemical composition and
mass concentration [3]. An increased surface area of the identical chemical may enhance surface
reactivity, adsorption properties, and potential toxicity [12,55]. Animal toxicity studies have indicated
that inhalation exposure to NPs can lead to more severe inflammatory responses compared to larger
particles of similar composition and mass, mainly due to their surface characteristics [15]. UFPs may
cause more inflammatory responses, more likely due to the large surface area [32,56,57]. An increased
surface area of inhaled NPs can be sufficient to initiate inflammation [38].
The interaction of NMs with cellular chemistry can induce ROS generation and hence the
generation of free radicals [10,12,15,42,58]. Free radicals are able to cause oxidative stress, tissue
inflammation, and damage to cells, membranes, proteins, and DNA [31,40,42–44,56,57,59]. It was
reported that UFPs can induce greater inflammatory responses in the rat lung compared to larger fine
particles through pathways other than the release of transition metals [60]. Larger particle surface areas
and increased intracellular Ca++ that involves oxidative stress are probably responsible for greater
inflammatory responses. Oxidative stress is a common mechanism responsible for toxicity of NMs,
either through direct generation of ROS at the surface of NPs or indirectly by target cells following the
internalisation of NPs [3].
The cytotoxicity of silver NPs has been potentially mediated through oxidative stress, ROS
generation, glutathione depletion, as well as mitochondrial membrane potential reduction [48,61].
Exposure of human pulmonary epithelial cells to SiO2 NPs led to ROS generation and glutathione
depletion in A549 cells [62]. In addition to ROS generation, the cytotoxicity of silica NPs was found to be
related to alteration of membrane integrity induced by cellular uptake [58]. The toxicity investigations
of a few metal oxides in human A549 lung cells revealed that the CuO NPs were highly toxic,
inducing cytotoxicity, DNA damage, oxidative injuries, and intracellular ROS [44,63]. Following the
investigation of the molecular mechanisms of toxicity of different forms of Cu, poly-dispersed CuO
NPs of less than 100 nm was found to be significantly more toxic than CuO NPs of 6 nm (NP6), Cu
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microparticles, and Cu2+ to A6 cells causing ROS generation, DNA damage, cell viability reduction,
glutathione depletion, and eventually cell death [63].
Pro-inflammatory effects were observed in human endothelial cells following exposure to NPs of
cobalt, SiO2, and TiO2, enhancing IL-8 cytokine production [47]. It has been suggested that CDNPs
originating from different sources are able to mediate various adverse effects in target organs including
lungs through pathways of oxidative stress, inflammation, and carcinogenesis [42]. In addition to
local inflammatory effects, NPs may be translocated into blood circulation. Blood-borne particles can
be delivered to secondary target organs such as the brain, heart, spleen, kidney, and liver, causing
additional systemic effects [38,42].
A small size, high surface reactivity, and surface chemistry significantly contribute to the
interaction of NPs with biological molecules. Toxicity analysis demonstrated that both size and
surface coating of iron NPs are critical determinants of cellular response and a potential mechanism
toward cytotoxicity [64]. Enhanced reactivity and distinctive surface characteristics of NMs, such as
those of metallic atoms and fractal geometries, may also increase the likelihood of toxic effects [59].
High surface area and exposed surface atoms and molecules promote increased dissolution and release
of ions from metallic or metal oxide NPs relative to their bulk materials. Metal ions are toxic to bacteria
and aquatic organisms by the inhibition of enzymes and transport proteins [3]. For example, Ag+
ions released from nanosilver particles significantly accounts for the antibacterial and toxic properties
of nanosilver particles [61,65]. ZnO NPs are another example of metal oxide NPs that can exhibit
cytotoxicity due to the rapid release of Zn2+ ions.
Acute exposure of human vascular endothelial cells to NPs of yttrium or zinc oxides upregulated
mRNA levels of inflammatory markers significantly; however, no inflammation was initiated by iron
oxide NPs in human vascular endothelial cells [49]. Biological impacts of carbon black (CB) and TiO2
NPs were compared in rats, and it was concluded that ultrafine CB induced greater inflammation
and epithelial damage than TiO2 NPs [57]. Such findings suggest that the composition and surface
characteristics of NPs may significantly contribute to their biological impacts such as inflammation.
Several modalities of cell death may be induced by CB and TiO2 NPs in human cells, inducing distinct
molecular mechanisms of toxicity [66]. NPs therefore may induce cytotoxicity via several mechanisms:
those that are identical may represent general pathways of nanotoxicity, and others that are specific to
each NP could be associated with their specific physicochemical characteristics.
NMs have an increased potential to travel through the living organism compared to identical
materials of the larger scale [42,52]. Regarding the ability of some NMs to deliver drugs throughout
the human body, they may also be able to bind with and transport toxic chemicals and other pollutants.
Airborne nanoparticles may work as vehicles to carry toxic chemicals and co-contaminants into the
human body via the respiratory tract [24]. Significant growth in the development and production of
engineered NPs can increase the potential for interactions of NMs with environmental media including
the air. Carefully designed toxicity studies are required to understand the potential toxic interactions
of NPs with other air toxicants such as organic compounds.
Exposure to chemical mixtures or complex atmospheres has already raised the concern of
producing unexpected outcomes due to chemical or physiological interactions [26]. Multiple chemical
exposures may induce a diverse range of toxic effects including respiratory symptoms and lung
function defect [67]. The biological interactions of different NPs are not known, but the common
pathway of oxidative stress suggests that there is a significant potential for chemical interactions such
as additive or synergistic effects that need to be considered in future research [42].
Owing to their high energetic surface properties and adhesive forces, NPs may act like activated
charcoal for the adsorption of other small molecules [38]. The large surface area of NPs provides a
platform towards adsorption of various biological molecules including proteins, lipids, and nucleic
acids. The rapid binding of proteins and NPs in biological fluids is defined as “protein corona”,
but the biological consequences of protein adsorption to NPs are less clear. An example of serum
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protein adsorption is the binding of fibrinogen and NPs with the potential consequence of blood clot
formation [68].
Biopersistency of engineered NMs, which is associated with dissolution, is an important factor
influencing environmental and biological toxicity. Those NPs for which dissolution appears to be
very rapid, such as ZnO NPs, biopersistence can be considered unlikely. However, in the case of
extremely insoluble NPs such as carbon-based NMs, the potential for bioaccumulation inside living
systems will be increased. Water solubility was found to be significantly associated with the toxicity
of NPs [69]. While soluble NMs may provoke acute toxicological responses, insoluble or extremely
low soluble NPs may cause a diverse range of chronic effects including carcinogenicity. Insoluble NPs
have the potential to reside for years in the respiratory tract [38]. As mentioned previously, the
phagocytic function of alveolar macrophages can be impaired following nanoparticle and nanofibre
exposure [31,32]. Following long-term low-level repeated exposures, this property will increase the
likelihood of adverse health effects. For example, CNTs that are finer than asbestos fibres, extremely
strong, and highly biopersist in the lung, are likely to cause diseases (e.g., pleural mesothelioma)
through similar pathogenicity [18,70,71].
NPs have a strong tendency to form aggregates and agglomerates in solid state and in many cases
in liquid suspension [3]. Zeta potential is a common indicator of surface charge indicating the electrical
potential at the outer surface of the spherical particle and adjacent water molecules traveling with
the particle during its motion. Sodium chloride and other ions reduce zeta potential by screening the
particle surface charge, often causing aggregation [3]. This property is a complicating factor in toxicity
testing of NPs.
It is critical to develop an integrated strategy for toxicity testing of NMs including both in vitro
screening and prioritisation for chronic animal testing [3]. Exploration of toxicity at the cellular
and molecular levels is of great importance [61]. The concentration of NPs, particle size and size
distribution, particle geometry, surface area, surface characteristics including surface coatings, the
route of exposure, the duration of exposure, ion generation, protein NP corona formation, and the
physicochemical characterisation of NPs are potential critical factors relating to toxicity [12,61,64,72].
4. Toxicity Assessment of NPs
In the US, it is expected that the comprehensive long-term toxicity testing of NPs using
experimental animals would require approximately 34–53 years and the cost of $1.18 billion [73].
Therefore, it is critical to develop alternative methods in order to determine toxicology profiles of NPs.
In that case, the application of in vivo test methods would potentially be reduced to studies such as
toxicokinetics, pulmonary inflammation, and potential models of fibrosis.
A wide variety of in vitro assays are available to assess cellular toxicity [74]. The most frequently
used in vitro assays to assess the cytotoxicity and biological responses of NPs have been reviewed [12,75].
Researchers often tend to implement comparatively simple in vitro test systems that are relatively easy
to perform, control, and interpret. However, there is a need to develop validated in vitro assay systems
for toxicity testing of an expanding range of NPs.
In the field of respiratory toxicology, in vitro methods have been developed using human-based
cellular systems such as airway cells, lung cells or tissues, and target-specific endpoints [27,76].
Potential pulmonary toxicity of NPs can be revealed using human lung cells in vitro and relevant
biological endpoints [74,77]. Validated in vitro test systems can provide readily available toxicity
information relevant to inhalational NM exposure. Such methods would bring many potential benefits
for the risk assessment of NPs, providing simpler, faster, and less expensive toxicity screening tools [78].
Regarding particle toxicology in vitro test methods using both human- and animal-based
cellular systems can be employed. However, appropriate lung cell types need to be selected
in order to represent significant features of its corresponding region in the respiratory tract.
Physiologically relevant in vitro models that are able to replicate the natural cellular structure and tissue
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architecture of the proximal and distal parts of the respiratory tract are essential for nanotoxicology
investigations [74,77].
Considering the complex nature of the architecture of the human lung, various in vitro models
may be employed to represent the proximal and distal regions of the respiratory tract, among
which cells and cell lines of the human airway (e.g., calu-3 human cell line) and alveolar epithelium
(e.g., A549 human lung cells) were employed in nanotoxicology more frequently [29]. In addition,
alveolar macrophages are among the first cellular systems dealing with inhaled material that can be
obtained both as primary cultures by pulmonary lavage or cell lines [79]. NPs can access deeply into
the distal lung where the pulmonary epithelium is composed of two distinct cell types of alveolar type
1 (AE1) and alveolar type II (AE2), serving essential functions of the alveolar epithelium. To represent
the multicellular nature and complex structure of the alveolar region, promising approaches for
construction of 3D alveolar tissue models in vitro have been reported [29,80–82].
In vitro methods can be precisely controlled; hence, they can provide more reproducible toxicity
data than in vivo models, but require higher standardisation [29]. Considering one of the major
technical challenges of in vitro toxicity testing of airborne contaminants, that is, to resemble inhalation
exposure in cultured cells or tissues, a significant breakthrough has been achieved [28,74,77,83–90].
Human cells cultured on permeable porous membranes exposed to airborne contaminants directly
at the air liquid interface (ALI) using exposure chamber systems. Direct exposure technique,
which provides close contact between target cells and airborne contaminants can be applied for
nanotoxicology investigations providing physiologically relevant toxicity information on NPs.
In order to allow for the efficient and homogeneous distribution of fine and ultrafine aerosols into
the human cells cultured on the membrane surface, the commercially available perfusion chamber
system of MINUCELL was modified [91]. The uniform particle deposition and the well-defined dose
were achieved by a continuous monitoring of the particle size distribution [92].
For exposure of target cells to NPs directly at the air-liquid interface, the Karlsruhe exposure
system (Vitrocell, Hannover, Germany) was implemented [93,94]. This system was equipped with a
modified isokinetic sampling unit for aerosol collection from the particle-loaded air. Particles >1 µm
were removed prior to exposure using a size-selective sampler such as a cyclone. A quartz crystal
microbalance was also used to monitor the deposited mass per area unit to determine the accurate
dose reached for target cells.
Adjustments were also made to the CULTEX (Vitrocell, Germany) system utilising inlet tubes with
a hyperboloid-shaped air distribution unit constructed from Teflon or stainless steel, providing up to
80% deposition efficiency for NPs [83,95]. More recently, the CULTEX radial flow system was designed
specifically for the exposure of cells to micro- and nanosized particles, implementing computational
fluid dynamics (CFD) analysis to confirm an efficient, reproducible, and homogeneous deposition of
particles [17]. Therefore, in vitro exposure methods that meet the essential requirements of the toxicity
testing of airborne contaminants can be applied in parallel with real-time air monitoring techniques
for toxicological risk assessments of NPs.
5. Risk Management of NPs
The vast diversity of engineered NMs and their great potential for commercial applications have
introduced significant challenges for risk assessment and management. While the risk management
framework provides a systematic and scientific approach for risk characterisation, application of such
a framework to NMs often involves uncertainty factors significantly larger when compared to other
chemicals or pharmaceuticals. The International Organization for Standardisation (ISO) has established
a number of technical reports to provide a framework for risk assessment of nanotechnologies such as
ISO/TR12855 and ISO/TR13121 [96,97]. The later technical report provides a framework for hazard
identification, risk evaluation, decision options, and the risk communication of manufactured NMs in
order to protect health and safety of exposed populations, including the general public, consumers and
workers as well as the environment [97]. While the risk assessment framework is not unique to NMs,
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the process is focused on engineered NPs used in industrial settings, chemical manufacturing, and
consumer product applications and on the potential risks related to the release of NMs during their life
cycle. This technical report supplements issues specific to manufactured NMs and includes admitting
where information is not complete, how to address information gaps, and the rationale behind risk
management decisions and actions. The recommended process can be summarised in Table 3 [97,98].
Table 3. Risk management framework relevant to nanomaterials.
Risk Management Details of Each Step Relevant to Nanomaterials
Identify hazard






Based on the combination of: Identified hazards, exposure, potential risks
Exposure patterns: including likelihood and severity
Control risk
Level 1: Eliminate the hazard
Eliminating the nanomaterial
Level 2: Substitute, Isolate and engineering controls
Substitute to a safer material, product or process
Apply process containment
Use local exhausted ventilation systems equipped with efficient filters (e.g., HEPA)
Level 3: Reduce exposure by
Administrative controls (e.g., develop Safety data sheets and safe work procedures)
Personal protective equipment (e.g., appropriate gloves, eye and respiratory protection)
Decide, document & act
Decide:
Whether or in what capacity to continue development and production of the nanomaterial
Sharing information with the stakeholders
Further information to be collected
Review & adapt Update the risk assessment process through: Regular reviews
Reviews triggered by specific events
Comprehensive NM characterisation is required for the risk assessment process.
Therefore, different NM profiles need to be developed including physicochemical profiles,
hazard profiles, and exposure profiles [97]. The unique physicochemical properties of solid materials
at the nanoscale level contribute to major technical limitations. Technical limitations may induce
misleading results generated by conventional toxicity assays. Several limitations have been discussed
with respect to toxicity testing of NPs [3]. For example, NPs can adsorb vital dyes, cell culture
micronutrients, or released cytokines due to their high surface area and hydrophobicity [75,99–102].
To prevent misinterpretation of in vitro data, there are significant issues that need to be addressed such
as inclusion of relevant controls, assessing the ability of particles to interfere with the assays, particle
dispersion, and using systematic approaches [75].
Considering toxicological and environmental studies, different types of data might be required
in relation to NPs including particle characterization, potential adverse effects, detection, and
quantification. While particle size distribution is a major physicochemical characteristic for
toxicological studies of NPs, other important parameters include surface area, surface reactivity, water
solubility, agglomeration, chemical composition, morphology as well as particle number, and mass
concentrations [29,38]. Currently, high-resolution imaging techniques such as transmission electron
microscopy (TEM) and scanning electron microscopy (SEM) serve as efficient tools to characterize
NMs regarding their size distribution, morphology, and structure [10,44,103].
However, the efficient characterisation and quantification of NPs may require a few analytical
techniques to be used together that may complicate the analysis and assessment of NMs [103].
Available methods of sampling and analytical techniques may not be capable enough to precisely
quantify the concentration of NPs [38,70,104]. Collaborative and interdisciplinary research teams
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of nanotoxicologists, chemists, engineers, and material scientists are required to investigate and
understand the NM properties and related biological interactions.
While it is possible to engineer NPs with desirable surface properties for commercial and
biomedical applications, toxic effects of NMs can also be minimised using safe methods of NM
design such as capping or coating of NPs [105,106]. While uncoated TiO2 NPs induced phototoxicity,
no phototoxicity was detected in a cell assay system following coating with hydrophobic stabilisers
used in sunscreen formulations [107]. As carbon nanotubes, fullerenes, and graphene are easily
surface-functionalised, it has been reported that covalent functionalisation with carboxyl groups
can decrease toxicity of these carbon-based NMs [105,108,109]. The therapeutic use of AgNP is
diverse, ranging from dentistry, cancer treatment, and virucidal applications to biosensors in diagnosis
and imaging [110]. While a dose-dependent cellular toxicity caused by AgNPs and Ag+ in A549
human lung-derived cells, the cytotoxicity of both silver compounds significantly decreased following
pre-treatment with the antioxidant N-acetyl-cysteine [111]. For safe fabrication and incorporation of
different shapes of AgNPs in collagen hydrogels, a method was developed recently by anchoring
NPs to a thio-modified LL37 peptide [112]. Upon subcutaneous implementation, no toxic effects
were observed on human endothelial and cornea epithelial cells, with no significant interleukin-6
activation. For inorganic NPs that are not cleared from the body, a possible solution is to target them to
hepatocytes in order to enhance the hepatobiliary clearance [113]. To reduce NP sequestration by the
liver, several strategies have been proposed such as shape, elasticity, and surface modifications of NPs.
The ultimate goal of mechanistic nanotoxicology is to develop structure activity relationships that can
assist the redesign of optimal and safe NMs for specific applications [3].
Exposure standards such as air quality and workplace exposure standards are recommended
for airborne contaminants; however, currently very limited toxicological data makes it difficult to
establish such guidelines for exposure to NPs. Considering the lack of firm toxicological and exposure
profiles, the hierarchy of control measures need to be implemented for the maximum protection of
human health and the environment. Strategies have been also introduced to evaluate unintentional
occupational exposures to nanoparticles [114,115]. ISO has provided two technical specifications on
occupational health and safety measures relevant to engineered NMs [116] and the use of the control
banding (CB) approach for the occupational risk management of engineered nanomaterials [117].
CB may be applied as a qualitative strategy to assess work-related risks of NMs and to select control
options [114]. CB applies categories or bands of health hazards that should be combined with exposure
potentials or exposure scenarios to predict the risk level. The selection of this control approach will
include a consideration of the level of risk involved. A practical guide has been recommended for
industrial hygienists on managing occupational risks associated with engineered NMs, providing
guidance on conducting workplace exposure assessment and risk characterization accounting methods
of monitoring and describing criteria for risk management options [115].
6. Conclusions
While many potential benefits are expected from the development and commercialisation of NM
products worldwide, the associated risks of exposure to NPs may often be ignored due to the lack of
available toxicity information. Both acute and chronic adverse effects may arise following exposure
to NPs and UFPs, ranging from inflammation, asthma and metal fume fever to fibrosis, chronic
inflammatory lung disease, and carcinogenesis [38,42,56]. Such consequences caused by unintentional
or deliberate exposures may pose health risks to exposed populations. While working populations
that are engaged in the research and production of NPs may have the greatest potential for exposure,
by increasing the commercial application of NM products, exposure potential for the general public is
also expected to increase.
Biological interactions and toxic effects of NPs is significantly associated with their unique
physiochemical properties [12,32,56]. At the nanoscale level, physical and chemical characteristics, as
well as biological effects of NMs, can be changed significantly compared to the identical material of
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larger particles [38]. Therefore, it is likely for NPs to act like molecular-sized particles or to have hybrid
properties of a molecule and a particle. Such unique nano-properties may pose a major challenge for
risk assessment [59,103].
Rapidly expanding development and commercial application of NMs can increase the potential
interactions of NPs with biological systems including human health. More research is required to
explore the toxicity of NPs and their underlying mechanisms to support toxicological risk assessment
as an integral part of nanotechnology-based product development [38,118]. Cellular uptake of NPs
and cell-particle interactions are significantly determined by the physicochemical properties of NPs,
experimental and exposure conditions, and cellular types [12,61,64,72]. Standardised in vitro methods
have the potential to be applied as an initial step towards developing the toxicology profile of NPs.
There are many uncertainties regarding the risk assessment of NM exposure. However, strategies
have been introduced to evaluate and manage the unintentional human exposure to nanoparticles,
particularly occupational exposures. In the absence of adequate exposure and toxicological profiles,
the hierarchy of control measures need to be implemented to ensure the protection of human health
and to avoid underestimating the potential risks of human nanomaterial exposure.
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